The 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases returns to Boston this fall. Ensure you join this year’s 150+ expert community in-person to: Uncover recent studies evaluating critical inflammatory and auto-immune pathways Gain a deeper understanding of promising biologics targeting IL-13, IL-31, IL-33, versus IL-17 associated diseases Assess emerging efficacious targeted approaches […]

Returning to Boston for 2022, the 6th Microbiome Movement- Human Nutrition Summit is the only industry focused meeting dedicated to exploring the latest innovations, practical applications and clinical benefits of microbiome targeting food, beverages and supplements to pave the route to commercial success in the consumer health setting. Get up to speed on this dynamic industry with […]

Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from IPF, NASH, CKD and more in one place at one time, so you can advance the progress of your antifibrotic therapies. From exploring cellular mechanisms to identify a common fibrotic pathway to bridging the translational gap […]

SAE Media Group’s Inaugural Conference… Medical Devices and IVD 2022 14 – 15 November 2022 London, UK www.medicaldevices-ivd.com/PJ Navigating The MDR and IVDR and Best Strategies for Compliance  SAE Media Group is proud to announce the launch of the Medical Devices and IVD Conference, taking place on 14 – 15 November 2022 in London, UK. […]

The 7th Annual Microbiome Connect: USA 2022 is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis. As the first FDA approved microbiome-targeted therapeutic emerges, drug developers will have the opportunity to benchmark their rational drug platforms, targeting validated […]

Recognize Disease Hallmarks Earlier for Improved Patient Outcomes Gain Clarity Across Next Generation Non-Invasive Testing Technologies Revolutionizing Cancer Monitoring, MRD & Earlier Detection to Support Novel Pre-Metastatic Drug Development with Maximized Access In the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca, Amgen & Bristol Myers Squibb the liquid […]

Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders With more clinical data emerging, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers, catapulting this critical field forwards. Join 100+ peers this November at the 2nd Rare […]

The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never […]

Recognized with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and […]

The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma, biotechs, and academic KOLs, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs, which are shaking up the immunology R&D landscape. As the space eagerly awaits data readouts from proof-of-concept trials, and with more companies than […]

The first wave of investment in NASH is dispersing in the wake of highly demanding biopsy endpoints, but opportunities to target obesity and metabolic syndrome are catalyzing increasing excitement. Pivotal readouts in GLP-1 receptor agonists and exciting progress in regenerative medicine and microRNAs are redefining the drug development landscape for metabolic disorders. With mounting competition […]

The time has come to remove the pharmaceutical industry’s reliance on archaic off-line testing and embrace the cost and speed-to-market savings of online control and real-time product quality. The PAT market is projected to reach USD 4.96 Billion by 2027, spurred on by the recent ICH Q14/ Q2 (R2) guidelines, there has never been a more […]